The role of transforming growth factor-beta in identifying patients with coronary artery disease
Апстракт
Transforming growth factor-beta (TGF-beta) is a cytokine with antiatherogenic propretis. The active form of TGF-beta inhibits the activation of endothelial cells, and acts on vascular smooth muscle cells by inhibiting their migration, dediferentiation and proliferation. Lipoprotein (a) i PAI-1 interfere with plasmin-mediated TGF-beta activation by inhibiting the conversion of plasminogen to plasmin. Genetic polymorphism in the TGF beta(1) gene promoter were shown to be correlated with total TGF-beta concentrations, as measured by ELISA after acetic acid/urea activation. Althought many patients with coronary artery disease (CAD) have total TGF-beta concentration below the detection limit, the ability of total TGF-beta assay in discriminating between patients with CAD and individuals with normal coronary arteries is rather limited. Very significant inverse relationship between the concentration of active TGF-beta and CAD was found in several retrospective studies. Minor overlapping betwe...en the values in CAD patients and controls was obtained, demostrating the potential of the active TGF-beta as a new marker of CAD, superior to any of the conventional risk factors.
Кључне речи:
Atherosclerosis / Coronary disease / Transforming growth factorИзвор:
Jugoslovenska medicinska biohemija, 1999, 18, 2-3, 85-89Издавач:
- Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd
Институција/група
PharmacyTY - JOUR AU - Stanojević, N AU - Jelić-Ivanović, Zorana AU - Durović, S AU - Spasojević-Kalimanovska, Vesna PY - 1999 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/212 AB - Transforming growth factor-beta (TGF-beta) is a cytokine with antiatherogenic propretis. The active form of TGF-beta inhibits the activation of endothelial cells, and acts on vascular smooth muscle cells by inhibiting their migration, dediferentiation and proliferation. Lipoprotein (a) i PAI-1 interfere with plasmin-mediated TGF-beta activation by inhibiting the conversion of plasminogen to plasmin. Genetic polymorphism in the TGF beta(1) gene promoter were shown to be correlated with total TGF-beta concentrations, as measured by ELISA after acetic acid/urea activation. Althought many patients with coronary artery disease (CAD) have total TGF-beta concentration below the detection limit, the ability of total TGF-beta assay in discriminating between patients with CAD and individuals with normal coronary arteries is rather limited. Very significant inverse relationship between the concentration of active TGF-beta and CAD was found in several retrospective studies. Minor overlapping between the values in CAD patients and controls was obtained, demostrating the potential of the active TGF-beta as a new marker of CAD, superior to any of the conventional risk factors. PB - Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd T2 - Jugoslovenska medicinska biohemija T1 - The role of transforming growth factor-beta in identifying patients with coronary artery disease VL - 18 IS - 2-3 SP - 85 EP - 89 UR - https://hdl.handle.net/21.15107/rcub_farfar_212 ER -
@article{ author = "Stanojević, N and Jelić-Ivanović, Zorana and Durović, S and Spasojević-Kalimanovska, Vesna", year = "1999", abstract = "Transforming growth factor-beta (TGF-beta) is a cytokine with antiatherogenic propretis. The active form of TGF-beta inhibits the activation of endothelial cells, and acts on vascular smooth muscle cells by inhibiting their migration, dediferentiation and proliferation. Lipoprotein (a) i PAI-1 interfere with plasmin-mediated TGF-beta activation by inhibiting the conversion of plasminogen to plasmin. Genetic polymorphism in the TGF beta(1) gene promoter were shown to be correlated with total TGF-beta concentrations, as measured by ELISA after acetic acid/urea activation. Althought many patients with coronary artery disease (CAD) have total TGF-beta concentration below the detection limit, the ability of total TGF-beta assay in discriminating between patients with CAD and individuals with normal coronary arteries is rather limited. Very significant inverse relationship between the concentration of active TGF-beta and CAD was found in several retrospective studies. Minor overlapping between the values in CAD patients and controls was obtained, demostrating the potential of the active TGF-beta as a new marker of CAD, superior to any of the conventional risk factors.", publisher = "Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd", journal = "Jugoslovenska medicinska biohemija", title = "The role of transforming growth factor-beta in identifying patients with coronary artery disease", volume = "18", number = "2-3", pages = "85-89", url = "https://hdl.handle.net/21.15107/rcub_farfar_212" }
Stanojević, N., Jelić-Ivanović, Z., Durović, S.,& Spasojević-Kalimanovska, V.. (1999). The role of transforming growth factor-beta in identifying patients with coronary artery disease. in Jugoslovenska medicinska biohemija Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd., 18(2-3), 85-89. https://hdl.handle.net/21.15107/rcub_farfar_212
Stanojević N, Jelić-Ivanović Z, Durović S, Spasojević-Kalimanovska V. The role of transforming growth factor-beta in identifying patients with coronary artery disease. in Jugoslovenska medicinska biohemija. 1999;18(2-3):85-89. https://hdl.handle.net/21.15107/rcub_farfar_212 .
Stanojević, N, Jelić-Ivanović, Zorana, Durović, S, Spasojević-Kalimanovska, Vesna, "The role of transforming growth factor-beta in identifying patients with coronary artery disease" in Jugoslovenska medicinska biohemija, 18, no. 2-3 (1999):85-89, https://hdl.handle.net/21.15107/rcub_farfar_212 .